FDA warns of cardiac risk with stress test agents

FDA warns of cardiac risk with stress test agents

(HealthDay)—The use of cardiac nuclear stress test agents comes with a rare but serious risk of heart attack and death, according to a warning sent by the U.S. Food and Drug Administration to health care professionals.

Lexiscan (regadenoson) and Adenoscan (adenosine), used in cardiac stress tests in patients who cannot exercise adequately, help identify coronary artery disease by dilating heart arteries and increasing blood flow. The risk stems from reduced blood flow to obstructed areas, which may result in potentially fatal .

The FDA has approved drug label changes for the two drugs to highlight these risks and update recommendations for their use. At this time, it is not clear if there is any difference in risk between Lexiscan and Adenoscan.

According to the agency, should "screen all candidates for their suitability to receive Lexiscan or Adenoscan. Avoid using these drugs in patients with signs or symptoms of unstable angina or cardiovascular instability, as these patients may be at greater risk for serious cardiovascular adverse reactions."

More information: More Information

Related Stories

Recommended for you

Moderate drinking in later years may damage heart

date May 26, 2015

Drinking two or more alcoholic beverages daily may damage the heart of elderly people, according to research in the American Heart Association journal Circulation: Cardiovascular Imaging. The study correl ...

Statins have benefits for asthma sufferers

date May 26, 2015

Statins continue to show that their benefits extend beyond their original focus of lowering high cholesterol. With the increasing prevalence of asthma, scientists are studying the effects of statins in the lungs. In a new ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.